hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06337357, orgStudyIdInfo id: NatGerHos-Sarcopenia, briefTitle: Results of Progressive Resistance Training in Older Type 2 Diabetic Patients With Sarcopenia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-09, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: National Geriatric Hospital, class: OTHER_GOV, descriptionModule briefSummary: A randomized controlled clinical trial that will test how progressive resistance training will impact outcomes of sarcopenia in older patients with type 2 diabetes who have been diagnosed as sarcopenia. The intervention will be 12 weeks in duration with approximately 24 sessions of resistance exercises. Outcome measures will be collected at baseline, 4, 8 weeks and 12 weeks., conditionsModule conditions: Sarcopenia, conditions: Diabetes, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Progressive Resistance Training, outcomesModule primaryOutcomes measure: Physical performance 1 - Handgrip strength, primaryOutcomes measure: Physical performance 2 - Gait speed, primaryOutcomes measure: Physical performance 3 - Short Physical Performance Battery (SPPB), primaryOutcomes measure: Muscle mass, secondaryOutcomes measure: Nutritional status, secondaryOutcomes measure: Health-related Quality of Life, secondaryOutcomes measure: Activities of Daily Living (ADLs) and Instrumental Activities of Daily Living (IADLs), eligibilityModule sex: ALL, minimumAge: 60 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: National Geriatric Hospital, city: Hanoi, zip: 100000, country: Vietnam, contacts name: Huyen TT Vu, PhD, role: CONTACT, phone: +84913531579, email: vuthanhhuyen11@yahoo.com, geoPoint lat: 21.0245, lon: 105.84117, documentSection largeDocumentModule largeDocs typeAbbrev: ICF, hasProtocol: False, hasSap: False, hasIcf: True, label: Informed Consent Form, date: 2024-01-23, uploadDate: 2024-03-22T11:34, filename: ICF_000.pdf, size: 212556, hasResults: False
protocolSection identificationModule nctId: NCT06337344, orgStudyIdInfo id: HSEARS20230213007, briefTitle: Neurophysiological Effects of Mind-body Exercise in Healthy Adults, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-01, primaryCompletionDateStruct date: 2024-04, completionDateStruct date: 2024-04, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: The Hong Kong Polytechnic University, class: OTHER, descriptionModule briefSummary: There is some clinical evidence showing that Baduanjin (BDJ) practice, a type of mind-body based physical exercise, can improve executive function (EF). However, the neurophysiological changes associated with improved cognitive function remain elusive. Therefore, this study aims to carry out randomised controlled trial to explore how the single-session BDJ practice affect the function of prefrontal cortex(PFC) and also the EF of healthy adults, measure by fNIRS and verbal fluency test accordingly. A total of 60 healthy adults (based on power analysis 80% (β= 0.20) chance (α = 0.05, two-tailed)), aged 18 to 40 year old, without any physical, neurological, and neuropsychiatric disorder, classified as right-handed by Edinburgh Handedness Inventory, also with normal intelligence as verified by the Test of Nonverbal Intelligence will be recruited and randomly assigned to treatment(i.e. BDJ), active control(i.e, exercise), and passive control(i.e. video viewing) group. The investigator anticipate that this single-session BDJ practice will result in - (1) enhancing executive functioning, and (2) changes in functional brain activation pattern in PFC in adults. The result will give a spotlight to neurophysiological treatment effect of single-session Baduanjin on healthy adults, in developing intervention for improving executive functioning of adults., conditionsModule conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Baduanjin, interventions name: Exercise, interventions name: Video Viewing, outcomesModule primaryOutcomes measure: Change in cognitive function as assessed by verbal fluency task (VFT), primaryOutcomes measure: Hemodynamic changes as assessed by fNIRS, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule locations facility: The Hong Kong Polytechnic University, status: RECRUITING, city: Hung Hom, state: Kowloon, country: Hong Kong, contacts name: Yvonne Han, PhD, role: CONTACT, phone: +852 2766 7578, geoPoint lat: 22.30715, lon: 114.18532, hasResults: False
protocolSection identificationModule nctId: NCT06337331, orgStudyIdInfo id: NSH 1401, briefTitle: Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08-31, primaryCompletionDateStruct date: 2026-08-31, completionDateStruct date: 2027-08-31, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Northside Hospital, Inc., class: OTHER, descriptionModule briefSummary: Patients eligible for a mismatch allogeneic stem cell transplant will receive Venetoclax daily for 7 days prior to transplant in addition to the following chemotherapy regimen: Decitabine daily for 5 days, Fludarabine daily for 5 days, and Busulfan daily for 2 days followed by 1 day of total body irradiation. Stem cell transplant will occur thereafter., conditionsModule conditions: Acute Myeloid Leukemia, conditions: Myelodysplastic Syndromes, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 23, type: ESTIMATED, armsInterventionsModule interventions name: Venetoclax, interventions name: Decitabine, interventions name: Fludarabine, interventions name: Busulfan, interventions name: Total Body Irradiation, outcomesModule primaryOutcomes measure: Incidence of relapse/progression by conducting blood and bone marrow biopsy evaluations at one-year post-transplant, secondaryOutcomes measure: Number of patients alive at one-year post transplant, secondaryOutcomes measure: Number of patients alive without recurrence of disease at one-year post transplant by conducting blood and bone marrow biopsy procedures, secondaryOutcomes measure: Number of patients who died one year post-transplant not related to recurrence of disease, secondaryOutcomes measure: Number of patients who fully engrafted (blood counts fully recovered) by conducting chimerism studies at 30-, 60-, 90-, 180-, and 365-days post transplant, secondaryOutcomes measure: Number of patients who developed acute graft-versus-host disease by recording signs and symptoms of acute GVHD according to MAGIC standards at one-year post-transplant, secondaryOutcomes measure: Number of patients who developed chronic graft-versus-host disease by recording signs and symptoms of chronic GVHD according to NIH standards at one-year post-transplant, secondaryOutcomes measure: Number of patients who are alive at one-year post transplant who also did not develop GVHD, secondaryOutcomes measure: Number of patients with treatment-related adverse events to venetoclax as assessed by CTCAE v5.0, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Caitlin Guzowski, city: Atlanta, state: Georgia, zip: 30342, country: United States, geoPoint lat: 33.749, lon: -84.38798, hasResults: False
protocolSection identificationModule nctId: NCT06337318, orgStudyIdInfo id: NCI-2024-02361, secondaryIdInfos id: NCI-2024-02361, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: S2308, type: OTHER, domain: SWOG, secondaryIdInfos id: S2308, type: OTHER, domain: CTEP, secondaryIdInfos id: U10CA180888, type: NIH, link: https://reporter.nih.gov/quickSearch/U10CA180888, briefTitle: Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08-31, primaryCompletionDateStruct date: 2032-03-31, completionDateStruct date: 2032-03-31, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: National Cancer Institute (NCI), class: NIH, descriptionModule briefSummary: This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden., conditionsModule conditions: Classic Follicular Lymphoma, conditions: Follicular Lymphoma With Unusual Cytological Features, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 600, type: ESTIMATED, armsInterventionsModule interventions name: Biospecimen Collection, interventions name: Computed Tomography, interventions name: Mosunetuzumab, interventions name: Positron Emission Tomography, interventions name: Rituximab, interventions name: Rituximab and Hyaluronidase Human, outcomesModule primaryOutcomes measure: 3-year milestone progression free survival (PFS), primaryOutcomes measure: PFS, secondaryOutcomes measure: Overall survival, secondaryOutcomes measure: Overall response rate, secondaryOutcomes measure: Event free survival (EFS), secondaryOutcomes measure: Incidence of adverse events, secondaryOutcomes measure: Restricted chance of longer PFS, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06337305, orgStudyIdInfo id: STUDY00146138, briefTitle: Resiliency in Patients Undergoing Radical Cystectomy for Bladder Cancer, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-08-19, primaryCompletionDateStruct date: 2022-08-19, completionDateStruct date: 2023-08-19, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: University of Kansas Medical Center, class: OTHER, descriptionModule briefSummary: This is a prospective cross-sectional survey-based study composed of both a retrospective chart review and 3-series patient survey. This study will help elicit potential areas throughout the perioperative course of radical cystectomy to improve patient resilience and quality of life, providing opportunity for future interventional studies., conditionsModule conditions: Bladder Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 74, type: ACTUAL, armsInterventionsModule, outcomesModule primaryOutcomes measure: Change in resiliency as measured by the Connor-Davidson Resilience Scale (CD-RISC-25)., primaryOutcomes measure: Change in quality of life in patients undergoing radical cystectomy as measured by the Functional Assessment of Cancer Therapy-Bladder-Cystectomy (FACT-Bl-Cys)., primaryOutcomes measure: Change in quality of life in patients undergoing radical cystectomy as measured by the PROMIS-29., secondaryOutcomes measure: Identification of clinical and demographic factors in bladder cancer patients, secondaryOutcomes measure: Demographics, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Kansas Medical Center, city: Kansas City, state: Kansas, zip: 66160, country: United States, geoPoint lat: 39.11417, lon: -94.62746, hasResults: False
protocolSection identificationModule nctId: NCT06337292, orgStudyIdInfo id: IRB00440042, briefTitle: Incisional Negative Pressure Wound Therapy to Reduce Infection and Complications in High-Risk Fractures: A Multicenter Randomized Controlled Trial, acronym: iVAC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2028-09-30, completionDateStruct date: 2028-12-31, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Major Extremity Trauma Research Consortium, class: OTHER, descriptionModule briefSummary: This is a multi-center, pragmatic, parallel arm randomized controlled trial (RCT) of 352 patients with high-risk open or closed tibial plateau fracture, high-risk open or closed tibial pilon fracture, or open tibial shaft fracture with incision \>3cm. Eligible participants will be randomized to receive either incisional negative pressure wound therapy (NPWT) or a non-suction standard-of-care wound dressing for their definitive wound management. The primary outcome will be a composite outcome to evaluate clinical status 3 months after randomization. The secondary outcomes will independently assess the components of the primary outcome., conditionsModule conditions: Fracture of Tibia, conditions: Wound Heal, conditions: Infected Wound, conditions: Wound Complication, conditions: Wound Dehiscence, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomization into study treatment arms (incisional NPWT or non-suction standard of care) will occur in variable permuted blocks, stratified by clinical center, in a 1:1 ratio. Patients will be randomized electronically by an online Data Management System maintained by the Coordinating Center at Johns Hopkins School of Public Health., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 352, type: ESTIMATED, armsInterventionsModule interventions name: Incisional Negative Pressure Wound Therapy (NPWT), outcomesModule primaryOutcomes measure: Complication composite outcome, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06337279, orgStudyIdInfo id: FMUUH-0322, briefTitle: Systemic Oxidative Stress Score as a Predictor of Gastric Cancer Survival and Recurrence Risk, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-12-10, primaryCompletionDateStruct date: 2023-08-20, completionDateStruct date: 2024-03-20, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Fujian Medical University, class: OTHER, collaborators name: Fujian Medical University Union Hospital, descriptionModule briefSummary: The Systemic Oxidative Stress Score (SOSS), a comprehensive score reflecting the oxidative stress conditions in the microenvironment, can independently and effectively predict tumor burden and long-term prognosis in GC patients. Nomograms based on SOSS provide a potential and promising model for risk stratification and guiding the implementation of treatment decisions., conditionsModule conditions: Gastric Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 3820, type: ACTUAL, outcomesModule primaryOutcomes measure: 5-year OS, primaryOutcomes measure: 5-year DFS, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fujian Medical University Union Hospital, city: Fuzhou, state: Fujian, zip: 350000, country: China, geoPoint lat: 26.06139, lon: 119.30611, hasResults: False
protocolSection identificationModule nctId: NCT06337266, orgStudyIdInfo id: 2024KY246, briefTitle: A Novel Online Calculator to Predict Long-term Survival and Recurrence Risk of Patients With Gastric Adenocarcinoma, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-01-01, primaryCompletionDateStruct date: 2023-08-20, completionDateStruct date: 2024-03-19, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Fujian Medical University, class: OTHER, collaborators name: Fujian Medical University Union Hospital, descriptionModule briefSummary: This study aimed to develop a novel Prognostic Oxidative Stress-Immune-Inflammatory Score (POSII Score) and introduce an innovative online calculator designed to predict long-term survival and assess the recurrence risk of gastric cancer (GC)., conditionsModule conditions: Gastric Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 3622, type: ACTUAL, armsInterventionsModule, outcomesModule primaryOutcomes measure: 5-year OS, primaryOutcomes measure: 5-year DFS, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fujian Medical University Union Hospital, city: Fuzhou, state: Fujian, zip: 350000, country: China, geoPoint lat: 26.06139, lon: 119.30611, hasResults: False
protocolSection identificationModule nctId: NCT06337240, orgStudyIdInfo id: pelvic floor exercise, briefTitle: Pelvic Floor Exercises Versus Pilates on Urinary Incontinance in Chronic Obstructive Pulmonary Disease, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-29, primaryCompletionDateStruct date: 2024-07-02, completionDateStruct date: 2024-07-02, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: The aim of the study is To compare between the effect of both pelvic floor and Pilates exercises on urinary incontinences in COPD patients., conditionsModule conditions: Urinary Incontinence, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Pelvic floor on COPD patients, interventions name: Pilates exercises on COPD patients, outcomesModule primaryOutcomes measure: Urinary incontinence (1 Hour and 24- Hour pad test), primaryOutcomes measure: Incontinence severity index:, secondaryOutcomes measure: Urinary incontinence quality of life questionnaire (I-QOL), secondaryOutcomes measure: Cough symptoms score, secondaryOutcomes measure: Cough symptoms questionnaire, secondaryOutcomes measure: The COPD Assessment Tool (CAT), eligibilityModule sex: FEMALE, minimumAge: 50 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Faculty of Physical Therapy, status: RECRUITING, city: Cairo, country: Egypt, contacts name: Donia El masry, doctorate, role: CONTACT, phone: 01005587119, email: donia.elmasry@cu.edu.eg, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06337227, orgStudyIdInfo id: 2/22, briefTitle: Potential Role of Sirtuins as Epigenetic Biomarkers of the Patient With Atherosclerosis or Calcific Aortic Stenosis, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-19, primaryCompletionDateStruct date: 2024-10, completionDateStruct date: 2026-10, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: IRCCS SYNLAB SDN, class: OTHER, collaborators name: Federico II University, descriptionModule briefSummary: The project aims to shed light on the role of Sirtuins, enzymes belonging to the third class of histone deacetylases (class III) involved in epigenetic modifications (deacetylation), focusing mainly on Sirtuin 6 (SIRT6), as a regulator of atherosclerosis and severe aortic valve stenosis through molecular-based and epigenetic studies in human VSMC cells., conditionsModule conditions: Atherosclerosis and Calcific Aortic Stenosis With and Without Diabetes, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 3, type: ESTIMATED, armsInterventionsModule interventions name: lncRNA signature analyses, outcomesModule primaryOutcomes measure: To evaluate by analysis of data obtained from NGS techniques whether and which proteins belonging to the Sirtuin family may be deregulated in patients with atherosclerosis or calcific aortic stenosis, secondaryOutcomes measure: To evaluate the experimental results achieved in the clinical-diagnostic context, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Irccs Synlab Sdn, status: RECRUITING, city: Naples, zip: 80143, country: Italy, contacts name: Monica Franzese, PhD, role: CONTACT, phone: +393334041413, email: direzionescientifica.irccssdn@synlab.it, geoPoint lat: 40.85216, lon: 14.26811, hasResults: False